on all orders above $300.00

FREE Pills!

via4gra pills

for free with every order



Less than in your
local pharmacy

Search by letter:

Krobicin (Biaxin)

Rating of sales:          


Krobicin is used to treat bacterial infections in many different parts of the body. It is also used in combination with other medicines to treat duodenal ulcers caused by H. pylori. This medicine is also used to prevent and treat Mycobacterium avium complex (MAC) infection.

Other names for this medication:
Abbotic, Aeroxina, Biaxin, Biclar, Clacee, Clarimax, Claripen, Clariwin, Clarix, Clonocid, Fromilid, Kalixocin, Karin, Klabax, Klabion, Klarithran, Klerimed, Kofron, Lekoklar, Macladin, Macrobid, Macrol, Moxifloxacin, Preclar, Synclar, Veclam, Zeclar

Similar Products:
Cipro, Zitromax, Erythromycin, Azithromycin, Roxithromycin, Erythrocin, Zmax, Zithromax, Ery-Tab, Dificid, Erythrocin Stearate Filmtab, Eryc, EryPed, Erythrocin Lactobionate, Ilosone, PCE Dispertab


Also known as:  Biaxin.


Krobicin (generic name: clarithromycin; brand names include: Maclar / Klaricid / Klacid / Clarimac / Claribid) is used to treat many different types of bacterial infections affecting the skin and respiratory system, including: Strep throat, Pneumonia, Sinusitis (inflamed sinuses), Tonsillitis (inflamed tonsils), Acute middle ear infections, Acute flare-ups of chronic bronchitis.

It also is used to treat and prevent disseminated Mycobacterium avium complex (MAC) infection [a type of lung infection that often affects people with human immunodeficiency virus (HIV)]. It is used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers.

It also is used sometimes to treat other types of infections including Lyme disease (an infection that may develop after a person is bitten by a tick), crypotosporidiosis (an infection that causes diarrhea), cat scratch disease (an infection that may develop after a person is bitten or scratched by a cat), Legionnaires' disease (a type of lung infection), and pertussis (whooping cough; a serious infection that can cause severe coughing). It is also sometimes used to prevent heart infection in patients having dental or other procedures.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Krobicin works by stopping the growth of or killing sensitive bacteria by interfering with their protein synthesis.


Krobicin Filmtab and Krobicin Granules may be given with or without food.

Krobicin XL Filmtab should be taken with food. Swallow Krobicin XL Filmtab whole; do not chew, break or crush Krobicin XL Filmtab.

Triple therapy: Krobicin Filmtab/lansoprazole/amoxicillin. The recommended adult dosage is 500 mg Krobicin Filmtab, 30 mg lansoprazole, and 1 gram amoxicillin, all given every 12 hours for 10 or 14 days.

Triple therapy: Krobicin Filmtab/omeprazole/amoxicillin. The recommended adult dosage is 500 mg Krobicin Filmtab, 20 mg omeprazole, and 1 gram amoxicillin; all given every 12 hours for 10 days. In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.

Dual therapy: Krobicin Filmtab/omeprazole. The recommended adult dosage is 500 mg Krobicin Filmtab given every 8 hours and 40 mg omeprazole given once every morning for 14 days. An additional 14 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.


Overdose symptoms may include severe stomach pain, nausea, vomiting, or diarrhea.


Store at room temperature between 20 and 25 degrees C (68 and 77 degrees F) away from moisture and heat. Keep container tightly closed. Protect from light. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Side effects

The most common side effects associated with Krobicin are:

  • krobicin 250 mg suspension
  • krobicin 250 mg 5 ml
  • krobicin 500 mg
  • krobicin suspension dosis
  • krobicin claritromicina 250 mg
  • krobicin suspension 250 dosis
  • krobicin suspension
  • krobicin claritromicina suspension
  • krobicin claritromicina suspension 250 mg
  • krobicin 125 mg
  • krobicin susp 125 mg
  • krobicin 125 mg 5 ml
  • krobicin 250 mg
  • krobicin susp 250 mg
  • krobicin claritromicina suspension 250
  • krobicin suspension 250 mg
  • krobicin suspension 250 mg dosis
  • krobicin suspension 125 mg
  • krobicin 250 mg precio

Side effect occurrence does not only depend on medication you are taking, but also on your overall health and other factors.


Discontinue immediately if hepatitis or severe hypersensitivity reactions occurs. Severe renal impairment. Proarrhythmic conditions (eg, hypokalemia, hypomagnesemia, bradycardia); avoid. Myasthenia gravis. History of porphyria; avoid concomitant ranitidine bismuth citrate. Elderly. Pregnancy (Cat.C): usually not recommended. Nursing mothers.

krobicin 125 mg

We used the standard methods of The Cochrane Collaboration. Data were extracted and analysed by two independent review authors.

krobicin suspension 125 mg

The addition of a nickel-free diet to standard triple therapy significantly increases the H. pylori eradication rate. The reduction of H. pylori urease activity due to the nickel-free diet could expose the bacterium to gastric acid and increase H. pylori's susceptibility to amoxicillin. Further studies are necessary to confirm this preliminary result.

krobicin 250 mg

Gastric MALT lymphoma is closely associated with Helicobacter pylori infection. Bacterial eradication therapy comprising clarithromycin is the first-line treatment in gastric MALT lymphoma patients. However, antimicrobial resistance to clarithromycin has been increasing in Europe, and thus far, it has not been examined in gastric MALT lymphoma patients. Based upon histopathological investigation, 17 adult gastric MALT lymphoma patients were identified to be related with H. pylori infection between 1997 and 2014. Detection of H. pylori infection in these patients and clarithromycin susceptibility testing were performed by 23S rRNA gene real-time PCR. Twelve of the patients were confirmed with H. pylori infection by real-time PCR. Among these patients, only two were found to be infected with clarithromycin-resistant H. pylori strain. In one of them, both the clarithromycin-resistant and sensitive genotype were detected. The rate of clarithromycin resistance was 15.4 %. Clarithromycin resistance pattern in gastric MALT lymphoma patients is under the predictions since a previous study performed in Central Europe revealed a rate of 36.6 % in Austria. Considering the low antimicrobial resistance rate, clarithromycin is still an option in gastric MALT lymphoma management.

krobicin claritromicina suspension

The susceptibility and serotypes of 211 strains of Streptococcus pneumoniae collected from 12 Spanish hospitals in December 2003 were studied. Susceptibility tests for eight antibiotics were carried out by E-test, and the serotype classification was carried out using pneumococcus antiserum from the Copenhagen Statens Serum Institute. Overall, the most frequent serotypes were 19 (12.2%); 6 (10.7%); 23 (10.2%); 3 (8.1%); 9 (6.6%); 14 (6.1%); and 29 (5.1%). In blood, the most frequent were 19 (16.6%) and 14 (11.9%), and 8.6% were nontypable. Under NCCLS (M7-A5) criteria, 55.6% of the strains were susceptible to penicillin (MIC < or =0.06 mg/l) and 7.9% showed high resistance (MIC > or =2 mg/l). Susceptibility to other antibiotics was 98% to moxifloxacin; 97.1% to levofloxacin; 94.6% to amoxicillin-clavulanic acid; 71.2% to cefuroxime; 84.4% to ceftriaxone; and 63.1% to clarithromycin and azithromycin. Only 13.3% of the strains showed susceptibility to the antibiotics tested. The greatest percentage of strains resistant to other antibiotics was found among the strains resistant to penicillin. Nine resistant phenotypes were detected.

krobicin claritromicina suspension 250

Clarithromycin significantly increased bosentan area under the plasma concentration-time curve of the dosing interval 3.7-fold and peak concentration 3.8-fold in all participants irrespective of the genotype. Clarithromycin also reduced CYP3A activity (midazolam clearance) in all participants; however, these changes were not correlated to the changes of bosentan clearance.

krobicin claritromicina 250 mg

A 7-year-old girl presented with subcutaneous emphysema, pneumomediastinum (PM), pneumoretroperitoneum, and pneumothorax caused by Mycoplasma pneumoniae (MP). The patient had been treated with clarithromycin for pneumonia at another hospital; however, her condition deteriorated and complications developed. Soon after admission to our hospital, we started the patient on minocycline and prednisolone, and the complications improved promptly. Laboratory data showed serum ferritin and urinary beta-2-microglobulin levels were greatly elevated. We therefore speculated that the patient might have underlying hypercytokinemia. Prednisolone is an effective treatment for hypercytokinemia. We therefore recommend prednisolone treatment for cases of severe M. pneumoniae pneumonia that do not respond to antimicrobial agents.

krobicin suspension 250 mg

Levofloxacin is believed not to influence the clearance of theophylline, although some new fluoroquinolones have been reported to do so. This case indicates that levofloxacin and clarithromycin inhibited theophylline metabolic pathways catalyzed by both CYP1A2 and CYP3A4 and resulted in the decrease in theophylline clearance. The clearance of theophylline, therefore, is not influenced by clarithromycin alone.

Target Point Shipping Method Tracking Delivery Time Price
Worldwide shipping

Worldwide shipping

Registered Mail  Not trackable 14-21 business days USD 20.00 per order
EMS  Trackable, where available 5-9 business days USD 30.00 per order

Delivery time is:

Registered Mail - 14-21 business days, prices - USD 20.00, no signature is required on delivery.
EMS - 5-9 business days, prices - USD 30.00, signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.

front back side

This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).

 Show Hide 
krobicin susp 125 mg 2017-06-01

A randomized, open-labeled, prospective controlled trial comparing sequential vs. standard triple-drug therapy was carried out at Lokmanya Tilak Municipal General Hospital, Mumbai. Two hundred and thirty-one patients with dyspepsia were randomized to a 10-day sequential regimen (40 mg of pantoprazole, 1 g of amoxicillin, each administered twice daily for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole, each administered twice daily for the remaining 5 Novamox Syrup 30ml days) or to standard 14-day therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily).

krobicin claritromicina suspension 250 2016-01-23

To estimate the recurrence rate of H. pylori in Israel using the database of the Azithral 100 Syrup Side Effects "Central H. Pylori Laboratory of Clalit Health Services".

krobicin 250 mg 2015-10-15

Intragastric bacterial load may affect both the outcome of eradication treatment and ulcer healing in patients with active duodenal ulcer Klimicin 300 Mg disease.

krobicin susp 250 mg 2016-12-23

Between July 17, 2013, and April 20, 2016, 5454 patients were screened for eligibility. Of these, 1620 patients were randomly assigned in this study. The eradication frequencies were 90· Tablet Cepodem 200 Mg 4% (488/540 [95% CI 87·6-92·6]) for 10-day bismuth quadruple therapy, 85·9% (464/540 [82·7-88·6]) for 10-day concomitant therapy, and 83·7% (452/540 [80·4-86·6]) for 14-day triple therapy in the intention-to-treat analysis. 10-day bismuth quadruple therapy was superior to 14-day triple therapy (difference 6·7% [95% CI 2·7-10·7, p=0·001), but not 10-day concomitant therapy. 10-day concomitant therapy was not superior to 14-day triple therapy. The frequency of adverse events was 67% (358/533) in patients treated with 10-day bismuth quadruple therapy, 58% (309/535) in patients treated with 10-day concomitant therapy, and 47% (252/535) in patients treated with 14-day triple therapy.

krobicin claritromicina suspension 250 mg 2017-06-29

One hundred patients were treated with pantoprazole Cefodox 100 Syrup plus clarithromycin and furazolidone for eradication. Clarithromycin and furazolidone resistance was evaluated by the agar dilution method. Point mutations in 23S rRNA genes related to clarithromycin resistance were investigated by polymerase chain reaction and restriction length fragment polymorphism and A by polymerase chain reaction. The data were analyzed by logistic regression.

krobicin 125 mg 5 ml 2016-07-27

Mycobacterium fortuitum is a rapidly growing Mycobacterium species that is a rare cause of disease, primarily in immunocompromised patients. We present a preterm very low Levocin 500 Mg Tab birth weight neonate who developed M. fortuitum bloodstream infection, where 16S rDNA sequencing allowed accurate identification. Cure was achieved by line removal and adjuvant combination treatment with amikacin, ciprofloxacin and clarithromycin.

krobicin claritromicina suspension 2017-08-26

A 70-year-old woman with methotrexate (MTX)-refractory rheumatoid arthritis (RA) was referred Amoclan Forte 625mg Dosage to our hospital for introduction of biological therapy. On high-resolution computed tomography scans, the patient exhibited abnormal findings such as bronchiectasis and centrilobular small nodules, which were highly suggestive of pulmonary nontuberculous mycobacterial (NTM) disease. Although mycobacterial cultures of sputum specimens yielded negative results, cultures of bronchoalveolar lavage fluids grew Mycobacterium abscessus. Frequent follow-up chest radiographs indicated that the patient's pulmonary disease became rapidly worse in 1 month following dose escalation of MTX and administration of low-dose prednisolone. Oral clarithromycin and levofloxacin, chosen on the basis of in vitro susceptibility testing, led to a dramatic recovery from this potentially life-threatening complication. Through our experience with this case, we have learned that (1) pulmonary M. abscessus disease can progress rapidly, even during nonbiological anti-RA therapy; (2) regular follow-up chest radiographs are useful to ensure timely implementation of anti-NTM treatment; (3) bronchoscopic testing should be considered when patients are suspected of pulmonary NTM disease but do not meet the diagnostic criteria; and (4) early isolation, identification, and susceptibility testing of causative NTM species are critical for favorable outcomes.